全文获取类型
收费全文 | 3396772篇 |
免费 | 238937篇 |
国内免费 | 6172篇 |
专业分类
耳鼻咽喉 | 48731篇 |
儿科学 | 108595篇 |
妇产科学 | 94531篇 |
基础医学 | 492770篇 |
口腔科学 | 97180篇 |
临床医学 | 301164篇 |
内科学 | 651155篇 |
皮肤病学 | 76059篇 |
神经病学 | 266645篇 |
特种医学 | 132165篇 |
外国民族医学 | 969篇 |
外科学 | 516109篇 |
综合类 | 71928篇 |
现状与发展 | 16篇 |
一般理论 | 1190篇 |
预防医学 | 258531篇 |
眼科学 | 80745篇 |
药学 | 253920篇 |
15篇 | |
中国医学 | 6891篇 |
肿瘤学 | 182572篇 |
出版年
2018年 | 37284篇 |
2017年 | 29458篇 |
2016年 | 31983篇 |
2015年 | 36913篇 |
2014年 | 50018篇 |
2013年 | 73305篇 |
2012年 | 103394篇 |
2011年 | 105608篇 |
2010年 | 62502篇 |
2009年 | 60735篇 |
2008年 | 98115篇 |
2007年 | 105851篇 |
2006年 | 106930篇 |
2005年 | 110398篇 |
2004年 | 107893篇 |
2003年 | 100859篇 |
2002年 | 94418篇 |
2001年 | 150549篇 |
2000年 | 153474篇 |
1999年 | 131103篇 |
1998年 | 37423篇 |
1997年 | 32912篇 |
1996年 | 32597篇 |
1995年 | 30919篇 |
1994年 | 28605篇 |
1993年 | 26946篇 |
1992年 | 103279篇 |
1991年 | 101029篇 |
1990年 | 99039篇 |
1989年 | 95921篇 |
1988年 | 88766篇 |
1987年 | 87297篇 |
1986年 | 82568篇 |
1985年 | 78945篇 |
1984年 | 58723篇 |
1983年 | 50002篇 |
1982年 | 29569篇 |
1979年 | 55361篇 |
1978年 | 39476篇 |
1977年 | 33381篇 |
1976年 | 31269篇 |
1975年 | 34861篇 |
1974年 | 41777篇 |
1973年 | 40017篇 |
1972年 | 37954篇 |
1971年 | 36012篇 |
1970年 | 33578篇 |
1969年 | 32081篇 |
1968年 | 29766篇 |
1967年 | 26945篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
991.
Jan M?schwitzer Rainer H Müller 《European journal of pharmaceutics and biopharmaceutics》2006,62(3):282-287
High pressure homogenization can be employed to produce drug nanocrystals with a number of advantages, like improved solubility behaviors, better drug targeting or even increased mucoadhesiveness. To obtain a controlled drug delivery system it is necessary to transform the resulting nanosuspension into a solid dosage form. The present study shows the feasibility to use a mucoadhesive nanosuspension of poorly soluble hydrocortisone acetate produced by high pressure homogenization as layering dispersion in a fluidized bed process, followed by the application of an enteric coating to achieve a controlled drug release. To point out the advantages of drug nanocrystals the new fomulation was compared with a formulation containing micronized drug. Both formulations were characterized with regard to their particle size and crystallinity by using laser diffractometry, photon correlation spectroscopy and X-ray diffraction. The pellet morphology was characterized by using the environmental scanning electron microscopy (ESEM). In the in vitro dissolution tests an accelerated dissolution velocity and an increased drug release could be shown for the pellets containing drug nanocrystals. 相似文献
992.
993.
994.
995.
Robin L. Bissinger MSN RNC NNP Cheryl A. Carlson MS RNC NNP 《Newborn and Infant Nursing Reviews》2006,6(2):87
Surfactant, a complex substance containing specific proteins and phospholipids, is essential for gas exchange in the lungs. Research shows that surfactant not only lowers surface tension, but also plays a role in host defense. Surfactant replacement therapy is a cornerstone in the treatment of respiratory distress syndrome in premature infants. New information on endogenous surfactant composition including surfactant apoproteins has led to advances in the surfactant replacement products currently available. Because of the success of surfactant deficiency treatment in neonates, surfactant replacement therapy has been studied in both the pediatric and adult population for the treatment of other respiratory disorders. This article describes the composition, metabolism, and function of endogenous surfactant and other uses of surfactant replacement therapies in neonates. 相似文献
996.
Targeted silencing of disease-associated genes by synthetic short interfering RNA (siRNA) holds considerable promise as a novel therapeutic strategy. However, unmodified siRNA can be potent triggers of the innate immune response, particularly when associated with delivery vehicles that facilitate intracellular uptake. This represents a significant barrier to the therapeutic development of siRNA due to toxicity and off-target gene effects associated with this inflammatory response. Here we show that immune stimulation by synthetic siRNA can be completely abrogated by selective incorporation of 2'-O-methyl (2'OMe) uridine or guanosine nucleosides into one strand of the siRNA duplex. These noninflammatory siRNA, containing less than 20% modified nucleotides, can be readily generated without disrupting their gene-silencing activity. We show that, coupled with an effective systemic delivery vehicle, 2'OMe-modified siRNA targeting apolipoprotein B (apoB) can mediate potent silencing of its target mRNA, causing significant decreases in serum apoB and cholesterol. This is achieved at therapeutically viable siRNA doses without cytokine induction, toxicity, or off-target effects associated with the use of unmodified siRNA. This approach to siRNA design and delivery should prove widely applicable and represents an important step in advancing synthetic siRNA into a broad range of therapeutic areas. 相似文献
997.
998.
999.
1000.